Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.

Sandro Pignata,Amit Oza,Geoff Hall,Beatriz Pardo,Radoslaw Madry,David Cibula,Jaroslav Klat,Ana Montes,Rosalind Glasspool,Nicoletta Colombo, Imre Pete, Ana Herrero Ibáñez,Margarita Romeo Marín, Rumyana Ilieva,Constanta Timcheva,Massimo Di Maio,Christopher Blakeley,Rosie Taylor,Alan Barnicle,Andrew Clamp

Gynecologic Oncology（2023）

引用 1|浏览19

暂无评分

摘要

Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC.

查看译文

关键词

BRCA mutation,HRR,Maintenance,Olaparib,Ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要